BURBANK, CA--(Marketwired - May 29, 2013) -
Imaging3™, Inc. (PINKSHEETS: IMGGQ
), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Tuesday May 21st and Wednesday May 22nd, 2013 the US Central District Bankruptcy Court held a plan confirmation hearing and confirmed the company's plan of reorganization.
"We look forward to moving out of the bankruptcy process and working towards getting Imaging3 fully reporting and compliant with SEC reporting requirements," stated Chairman/CEO Dean Janes. "We have a good deal of work ahead of us towards becoming a fully reporting public company as well as working towards resubmitting our 510k application with the FDA. More updates will be provided in the future in the form of filings and press releases, all of which can be followed on our website," stated Mr. Janes.
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at http://www.imaging3.com for more information.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.